It appears you are asking about Incruse Ellipta. Incruse Ellipta is a once-daily inhaled medication used for the long-term, maintenance treatment of bronchospasm and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). It is an anticholinergic bronchodilator that works by relaxing the muscles around the airways in the lungs, making it easier to breathe [1].
How does Incruse Ellipta work for COPD?
Incruse Ellipta contains the active ingredient umeclidinium, which is a long-acting muscarinic antagonist (LAMA). Umeclidinium blocks the action of acetylcholine, a chemical that causes smooth muscles in the airways to contract. By blocking acetylcholine, umeclidinium relaxes these muscles, widening the airways and improving airflow in patients with COPD [2].
When does patent exclusivity expire for Incruse Ellipta?
Information on the specific patent expiration dates for Incruse Ellipta (umeclidinium) can be found on specialized databases. For example, DrugPatentWatch.com provides detailed patent information, including expiry dates, for a wide range of pharmaceuticals [3].
What are the common side effects of Incruse Ellipta?
Common side effects reported with Incruse Ellipta include nasopharyngitis (common cold symptoms), headache, and chest pain. Other potential side effects may involve urinary tract infection, pain in extremities, and muscle spasms [1].
How does Incruse Ellipta compare to other COPD treatments?
Incruse Ellipta is a LAMA, a class of medication often used in COPD management. Other common classes include long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICS). Often, these medications are combined to provide more comprehensive symptom relief and exacerbation reduction. For instance, Incruse Ellipta is also available in combination products, such as Breo Ellipta (fluticasone furoate/vilanterol) and Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), which combine different mechanisms of action for enhanced efficacy [1][2]. The choice of treatment depends on the individual patient's needs and severity of COPD.
Can Incruse Ellipta be used for asthma?
Incruse Ellipta is indicated for the maintenance treatment of COPD. It is not approved for the treatment of asthma [1].
What are the risks associated with using Incruse Ellipta?
Potential risks with Incruse Ellipta include paradoxical bronchospasm, where breathing suddenly gets worse after using the inhaler. It may also cause or worsen urinary retention, particularly in patients with a history of bladder outlet obstruction or severe renal impairment. Caution is also advised in patients with narrow-angle glaucoma [1].
How is Incruse Ellipta administered?
Incruse Ellipta is delivered via the Ellipta inhaler, a once-daily dry powder inhaler. Patients are instructed to inhale the medication deeply through the mouthpiece to ensure it reaches the lungs [1].
Who manufactures Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What is the typical cost of Incruse Ellipta?
The cost of Incruse Ellipta can vary based on insurance coverage, pharmacy, and location. It is advisable to check with local pharmacies or insurance providers for specific pricing.
Sources:
[1] https://www.incruseellipta.com/
[2] https://www.drugpatentwatch.com/drug/umeclidinium
[3] https://www.drugpatentwatch.com/